H1 financial resultats
Category: Press release
Transgene and BioInvent to Present Updated Data on Armed Oncolytic virus BT-001 at ESMO 2025
ESMO 2025
Transgene Appoints Seasoned Industry Executive Emmanuelle Quilès to Board of Directors as Independant Director
Nomination E Quiles
Transgene Completes Initial Patient Screening in Phase II Part of TG4050 Trial in Operable Head and Neck Cancer
TG4050
Transgene to Participate in Upcoming Meetings with Biotech Industry Leaders
investor meetings
Transgene to Host Webcast on Positive TG4050 Head and Neck Cancer Data Presented at ASCO 2025
ASCO 2025 TG4050 webinar
Transgene and NEC Present Durable Disease-Free Survival and Sustained T Cell Responses at 24 Months with Individualized Cancer Vaccin TG4050
ASCO TG4050
Transgene to Present 24-month Disease-Free Survival Data from All Patients in Phase I Part of Trial of Individualized Cancer Vaccine, TG4050, at ASCO 2025
ASCO 2025 TG4050
Transgene to Present 24-month Disease-Free Survival Data from All Patients in Phase I Part of Trial of Individualized Cancer Vaccine, TG4050, at ASCO 2025
ASCO Abstract
Transgene and NEC Present Durable Disease-Free Survival and Sustained T Cell Responses at 24 Months with Individualized Cancer Vaccine TG4050
ASCO 2025 TG4050